July 24, 2024 08:00 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its […]
Financial
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
July 24, 2024 04:15 PM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, […]
Boston Scientific Announces Results for Second Quarter 2024
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
Magenta Medical Closes $105M Financing Led by Novo Holdings
Other new investors include Viking Global Investors and RA Capital Management Funding will support Magenta’s clinical programs in support of FDA approval for Elevate, the world’s smallest heart pump KADIMA, Israel, July 23, 2024 /PRNewswire/ — Magenta Medical, developer of Elevate™, the world’s smallest heart pump, has closed a $105M financing round led by global healthcare […]
Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 second quarter on Monday, August 12, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors.
GE HealthCare announces agreement to acquire clinical artificial intelligence business from Intelligent Ultrasound
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare’s portfolio of AI-enabled devices AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency Planned acquisition supports GE HealthCare’s precision care strategy to address inefficiencies and […]
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024.
Johnson & Johnson reports Q2 2024 results
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 […]
Le Bonheur Children’s and UT Health Science Center Announce Dr. Bret Mettler Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute
Dr. Mettler comes to Le Bonheur from Johns Hopkins Children’s Center
MEMPHIS, Tenn., July 17, 2024 /PRNewswire/ — Le Bonheur Children’s Hospital has named Bret A. Mettler, MD, its new Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute at Le Bonheur and the University of Tennessee Health Science Center. Dr. Mettler will also hold The Susan and Alan Graf Endowed Chair in Pediatric Heart Surgery at Le Bonheur.
He comes to Le Bonheur and UT Health Science Center from Johns Hopkins Children’s Center, where he serves as Director of Pediatric Cardiac Surgery and Co-Director of the Blalock-Taussig-Thomas Pediatric and Congenital Heart Center.
Before his time at Johns Hopkins, Dr. Mettler served as the Director of Cardiac Transplantation and Mechanical Circulatory Support at Vanderbilt University Medical Center in Nashville.
“I am excited for Dr. Mettler to join our talented and dedicated team at Le Bonheur and UT Health Science Center,” said Le Bonheur President Trey Eubanks, MD, FACS. “Bret brings a wealth of knowledge and experience which will allow us to continue our Heart Institute’s mission of providing excellent care for children with complex heart conditions.”
Dr. Mettler specializes in the surgical repair of complex congenital heart disease, heart transplantation and mechanical circulatory support. His research interests include insights into complex congenital heart defects and the development of an artificial pulmonary valve using stem cells.
“Le Bonheur is committed to excellence and providing outstanding care for patients,” said Dr. Mettler. “The Heart Institute has a world-class faculty built by Drs. (Chris) Knott-Craig and (Jeffrey A.) Towbin, and I am pleased to be part of building on that foundation. Le Bonheur really shines for its care for children in an environment built just for them. I am excited about our continued vision for growth and service to the community.”
Le Bonheur Children’s Announces Dr. Brett Mettler, page two of two
Dr. Mettler assumes the chief of Pediatric Cardiac Surgery and executive co-director of the Heart Institute roles from Christopher Knott-Craig, MD, who last year announced he plans to step down as chief and executive co-director of the Heart Institute. Dr. Knott-Craig, along with Dr. Jeffrey A. Towbin, the executive co-director of the Heart Institute and chief of Pediatric Heart Failure and medical director of Cardiomyopathy, Heart Failure and Heart Transplant Services, have been responsible for leading Le Bonheur’s Heart Institute to become a Top 10 program in U.S. News & World Report. They have built the reputation of Le Bonheur’s Heart Institute as an elite surgical and medical program and developed the new 31-bed Cardiovascular Intensive Care Unit. Le Bonheur will honor Knott-Craig and his tenure later this summer.
“I want to thank the medical, surgical and nursing members of the Heart Institute for their very substantial role in helping to recruit Dr. Mettler and for their long-term commitment to excellence and the special care given to their patients,” said Dr. Towbin, who also serves as chief of Cardiology at Le Bonheur and St. Jude Children’s Research Hospital and tenured professor, Department of Pediatrics, Pediatric Cardiology at UT Health Science Center. “I am excited for Le Bonheur’s future and for the innovation that Dr. Mettler brings to Memphis. He is a wonderful addition to our outstanding team.”
Dr. Mettler is a native of South Dakota. He, along with his wife Kelly and their two daughters, will move to Memphis later this year.
About Le Bonheur Children’s Le Bonheur Children’s, based in Memphis, Tenn., provides expert care for children in more than 45 pediatric subspecialties, encompassing robust community programs, a pediatric research institute and regional outpatient centers in Jackson, Tenn., Tupelo, Miss., and Jonesboro, Ark. Le Bonheur also features a 255-bed hospital in Memphis and a 21-bed satellite hospital within Jackson-Madison County General Hospital in Jackson, Tenn. As the primary pediatric teaching affiliate for the University of Tennessee Health Science Center, Le Bonheur trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur has been named a U.S. News & World Report Best Children’s Hospital for 13 consecutive years and is a Magnet-designated facility, the ultimate credential for high-quality patient care and nursing excellence.
For more information, please call (901) 287-6030 or visit lebonheur.org. Connect with us at facebook.com/lebonheurchildrens, x.com/lebonheurchild on Instagram at lebonheurchildrens.
About University of Tennessee Health Science CenterThe mission of the University of Tennessee Health Science Center is transforming lives through collaborative and inclusive education, research, scholarship, clinical care, and public service. With six colleges – Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy – at its main campus in Memphis, in addition to educational and clinical campuses at major hospitals in Memphis, Knoxville, Chattanooga, and Nashville, and sites across the state, UT Health Science Center strives to fulfill its vision: Healthy Tennesseans. Thriving Communities. For more information, visit www.uthsc.edu. You can find the University of Tennessee Health Science Center on Facebook, Instagram, LinkedIn, X, and YouTube.
CONTACT: David Henson(423) 304-9400 [email protected]
Ariss Arena (901) 283-5584 [email protected]
SOURCE Le Bonheur Children’s Hospital



